Imatinib is an effective first-line therapy for chronic myelogenous leukemia (CML) that acts by targeting the tyrosine kinase activity of BCR-ABL. To overcome resistance, secondgeneration inhibitors of BCR-ABL have been developed. Among these, nilotinib is more potent against BCR-ABL than imatinib, and is effective against many imatinib-resistant BCR-ABL mutants. In this study, an in vitro flow cytometry assay to analyze imatinib-and nilotinib-induced apoptosis in CML cells has been developed. Both the drugs induced significant apoptosis in CD34 þ cells from 36 CML bone marrow samples (Po10
Introduction
Chronic myelogenous leukemia (CML) affects 1-2 people per 100 000 each year. It is a clonal hematological disease originating in the hemopoietic stem cell by the translocation of the ABL gene in contiguity of the BCR gene. This translocation leads to a hybrid gene coding for the constitutively activated BCR-ABL tyrosine kinase. The tyrosine kinase inhibitor imatinib mesylate (Gleevec; Novartis Pharma, Basel, Switzerland) has been shown to potently inhibit this activity, besides that of the stem cell factor (SCF) and platelet-derived growth factor receptors, and shows remarkable potential as a component of novel frontline treatment regimens for CML. 1 However, some resistance to imatinib appeared in patients during treatment and a second generation of this drug family, nilotinib, was developed. This drug had a better specificity for BCR-ABL and a higher efficiency towards sensitive and resistant BCR-ABLexpressing cells. 2 Resistance mechanisms to nilotinib were also described and attributed to either mutations in the tyrosine kinase domain of BCR-ABL 3 or BCR-ABL over-expression. 4 BCR-ABL expression confers an apoptotic-resistant phenotype to the cells, which has been attributed to the expression of antiapoptotic proteins such as BCL-XL [5] [6] [7] and MCL-1, 8, 9 and the downregulation of the proapoptotic protein BIM. 9, 10 Both imatinib and the second-generation inhibitor nilotinib induce apoptosis of BCR-ABL-expressing cells, and this apoptosis is completely dependent on the expression of BIM. 11 However, this type of BIM-driven apoptosis simulates the death induced by cytokine deprivation 12 and has been essentially shown on cell lines, in cytokine-free medium. Conversely, a decrease in the tyrosine kinase inhibitor-induced apoptosis has been described in primary CML progenitor cells when cultured in the presence of cytokines. 4, 11, 13, 14 Apoptosis induction after the inhibition of specific oncogenic tyrosine kinases has been interpreted in terms of dependency of cancer cells on the pathway driven by this oncogene. 15, 16 This hypothesis of oncogene addiction was further supported by the successful therapies based on use of tyrosine kinase inhibitors in CML patients with imatinib, 1 or in case of non-small cell lung cancer with erlotinib. 17 However, it was recently reported that, in the presence of cytokines, CML progenitors showed limited oncogene addiction to BCR-ABL activity 18 and that pathways inhibited by tyrosine kinase inhibitors can be maintained in an activated stage in the presence of cytokines. 19 To investigate the relative importance of BCR-ABL tyrosine kinase inhibition and cytokine-dependant signaling inhibition in imatinib-and nilotinib-induced apoptosis, an in vitro flow cytometry assay was developed to analyze apoptosis induced on CML progenitors by these inhibitors.
The results showed that equitoxic concentrations of these molecules were affected differently by addition of a cocktail of cytokines, inhibiting almost completely the apoptotic effect of nilotinib. Finally, the protective effect of cytokines occurred through SCF-CD117 signaling and this differential effect was confirmed on the K562 cell line. On the basis of this and different findings described below, we conclude that the SCF-CD117 pathway must be inhibited, besides Bcr-Abl, to enable an apoptotic response.
Materials and methods

Cell lines
K562, a cell line established from a CML patient strongly expressing BCR-ABL and resistant to several apoptosis inducers, 20 was cultured in RPMI 1640 supplemented with 10% v/v fetal calf serum (FCS), 1 mM glutamine, 10 mM Hepes, 100 units/ml penicillin and 50 mg/ml streptomycin in a humidified atmosphere containing 5% v/v CO 2 at 37 1C. Exponentially growing cells were used in all experiments.
The cells were treated with either 2 mM imatinib (Novartis, Basel, Switzerland) or 20 nM nilotinib (Novartis, Basel, Switzerland). In some experiments, the cells were cultured in the presence of Stema.4B at 1:10 dilution (Stem Alpha, Lyon, France). This cocktail was used as a source of cytokines (interleukin (IL)3, IL6, SCF, erythropoietin, granulocyte macrophage colony-stimulating factor, IL11 and FLT3 ligand). When indicated, the cells were also incubated with 200 ng/ml human stem cell factor (R&D Systems Europe, Lille, France) or with 25 ng/ml anti-human SCF R (CD117) mouse monoclonal antibody (clone-47233, human stem cell factor, R&D Systems Europe, Lille, France). For apoptosis analysis, the loss of mitochondrial membrane potential (Dcm) was evaluated by flow cytometry using DiOC6(3) (3,3-dihexyloxacarbocyanine iodide) (100 ng/ml) as a probe. 21 The samples were analyzed with an Epics XL cytometer (Beckman-Coulter).
Patients
After informed consent was obtained, bone marrow aspirates or blood samples from patients with myeloproliferative disorders that were received in the laboratory for BCR-ABL analysis were separated by Ficoll sedimentation. Moreover, four normal bone marrow samples were taken during thoracoplasty surgery of non-hematological patients after informed consent. The mononuclear cell layer was washed and resuspended in culture medium in the presence of the drugs to be assayed and/ or the cytokine cocktail and/or SCF. After 24 h culturing, the cells were labelled with FITC-annexin V and PC5-conjugated anti-CD34 antibody (Beckman-Coulter, Villepinte, France). The CD34 þ cells were analyzed for annexin V binding after CD34 þ gating. Wherever indicated, phycoerythrin (PE)-conjugated anti-CD117 were also added and gating of apoptosis analysis was carried out on CD34 þ /CD117 þ and CD34 þ /CD117À cells. The samples were analyzed by flow cytometry with an Epics XL cytometer (Beckman-Coulter). After BCR-ABL analysis by reverse transcriptase-PCR, the samples were included either in the BCR-ABL expressing or in the BCR-ABL negative series.
Western blot analysis
Whole cell lysates were analyzed by western blot. The antibodies used were monoclonal mouse anti-a-tubulin (clone B-5-1-2, Sigma-Aldrich, France) and anti-Abl (clone 24-11, Santa-Cruz, Tebu, France).
shRNA experiments
Downregulation of BCR-ABL expression was obtained through lentiviral expression of shRNA as described earlier. 11 Oligonucleotide sequences for p210 BCR-ABL shRNA are 5 0 -AGCTT CCGCAGAGTTCAAAAGCCCTTTTCAAGAGAAAGGGCTTTTGA ACTCTGCTTTTTGGAAG-3 0 (forward) and 5 0 -GCAGAGTTCA AAAGCCCTTTCTCTTGAAAAGGGCTTTTGAACTCTGCGGA-3 0 (reverse). Oligonucleotides were annealed together and cloned into the HindIII-SalI site of the shuttle vector picHI. Then the H1 promoter/oligonucleotides cassette was removed by ClaI and SalI digestion and cloned into the pTRPdeltaU3MCS-EF1a-EGFP (enhanced green fluorescent protein) (gift from P Charneau, Pasteur Institute, Paris, France). Titers were determined by transducing 293T cells with serial dilution of lentiviral supernatant and analyzed for enhanced green fluorescent protein expression 5 days later. K562 cell lines were transduced at a multiplicity of infection of 3 and 30, respectively, in RPMI 10% FCS medium with or without human stem cell factor at 20 ng/ml. Transduction efficiency was checked by testing for enhanced green fluorescent protein expression by flow cytometry.
Statistical analysis
Results were expressed as the mean plus or minus standard deviation (s.d.). Data from fresh primary cells were analyzed with the Wilcoxon rank-sum test using the MedCalc software. Owing to the large range in spontaneous apoptosis during the culture of primary cells, the drug-induced apoptosis was calculated as the percentage of drug-specific apoptosis: (apoptosis in the presence of the drugÀapoptosis in control) Â 100/ (100Àapoptosis in control). The experiments on cell lines were carried out three times and analyzed with the paired Student's t-test using the Excel software.
Results
Imatinib and nilotinib induce BCR-ABL-dependent apoptosis in CD34 cells
Flow cytometry analysis of CML bone marrow mononuclear cells from 36 different samples collected at the time of diagnosis were incubated with 2 mM imatinib for 24 h,which showed that apoptosis could be efficiently detected in the subset of CD34 þ cells, whereas the proapoptotic effect was relatively attenuated in total bone marrow mononuclear cells ( Figure 1a ). It was observed ( Figure 1b ) that significant apoptosis was induced using total mononuclear cells by imatinib (P ¼ 0.012, n ¼ 36), but not nilotinib (P ¼ 0.06, n ¼ 29). However, the effects were much more prominent when the analysis was focused and gated on CD34 þ cells (Po10 À4 for both drugs) (Figure 1 ). When the analysis was gated on CD34 þ cells, both the sensitivity and specificity of the assay for BCR-ABL-expressing cells were higher than 0.9 (n ¼ 36 BCR-ABL þ and 12 BCR-ABL negative samples).
Nilotinib 20 nM and imatinib 2 mM induced a similar level of apoptosis and this was confirmed when the rate of nilotinibinduced apoptosis was plotted as a function of the rate of imatinib-induced apoptosis (Figure 1c) , with a trend line equation nearing y ¼ x (y ¼ 0.94x, n ¼ 26). A good correlation was found (R 2 ¼ 0.838) between the levels of apoptosis induced by imatinib and by nilotinib in CD34 þ cells, illustrating that both drugs acted on the same targets. In contrast, both drugs failed to induce a significant apoptosis in CD34 þ cells from 12 BCR-ABL negative hematological disorders and four normal bone marrow samples used as control (Figure 1b) , confirming the dramatic specificity of both inhibitors for BCR-ABL positive cells.
Cytokines overcome nilotinib-induced apoptosis of CML CD34 þ cells
Bone marrow mononuclear cells in liquid culture with 10% FCS as the sole supply of growth factors exhibited a high rate of spontaneous apoptosis after 24 h. However, addition of a cocktail of cytokines, including IL3, IL6, human stem cell factor, erythropoietin, granulocyte macrophage colony-stimulating factor , IL11 and FLT3 ligand, significantly decreased spontaneous apoptosis by 18% in control CD34 þ cells and by 26% in CML CD34 þ cells (P ¼ 0.0024, n ¼ 21) (Figure 2a ). The addition of cytokines also inhibited 22% of the imatinib-induced apoptosis (P ¼ 0.0041, n ¼ 20), which is in the same range as spontaneous apoptosis inhibition (Figure 2b, left panel) . In parallel experiments (Figure 2b , right panel), cytokine addition inhibited by 71% the nilotinib-induced apoptosis (Po10 À4 , n ¼ 20). This was significantly higher than inhibition observed on either imatinib-induced or spontaneous apoptosis (P ¼ 0.0014 and 10 À4 , respectively). In the presence of cytokines, the nilotinib-induced apoptosis remained proportional to imatinib-induced apoptosis; however, the slope was reduced by 58% (Figure 2c ), reflecting that cytokines could rescue from apoptosis twice more nilotinib-than imatinibtreated CD34 þ cells. Moreover, imatinib is known to inhibit not only BCR-ABL but also SCF receptor (CD117) tyrosine kinases at the concentration used (2 mM). Conversely, nilotinib is more specific and is not able to inhibit this receptor at the concentration used (20 nM). In our series, CML CD34 þ cells were positive for CD117 at a rate of 82.6±9.3% and, when CD34 þ cells were separated into CD117-expressing and CML apoptosis depends on c-KIT pathway inhibition F Belloc et al CD117À cells, the cytokine effect was mainly observed in CD117 þ CD34 þ cells (Figure 2d ). This suggests that the SCF could play an important role in the cocktail of cytokines.
The stem cell factor can replace BCR-ABL in maintaining survival of K562 cells
When K562 cells were treated by imatinib or nilotinib, either in the presence or in the absence of cytokines, imatinib-induced apoptosis was inhibited by 34% using the cocktail of cytokines, whereas nilotinib-induced apoptosis was inhibited by 71% ( Figure 3a) . However, the levels of Bcl-2, Bcl-XL, Mcl-1 and Bim proteins were not altered by the addition of cytokines, whereas the caspase 3 activation was greatly inhibited (Supplementary Figure S1 ). As compared with primary CML CD34 þ cells, the differential effect with both inhibitors in the presence of cytokines was confirmed on the CML cell line K562. To investigate whether c-KIT was related with the rescue of K562 cells using cytokines, K562 cells were treated by nilotinib in the presence of cytokines, with or without a blocking anti-CD117 antibody. The blockade of CD117 inhibited by 55% the antiapoptotic effect of the cytokine cocktail against nilotinib (Po0.05) (Figure 3b ). Using a proliferation assay, the IC50 of nilotinib was increased three times in the presence of cytokines, but twice only if anti-CD117 was added to cytokines (Figure 3c ). In this case, the IC95 that was found to be 20 nM in the absence of cytokines was not attained in the presence of cytokines. However, a very high concentration of nilotinib (3 mM), able to inhibit c-KIT tyrosine kinase, was also able to maintain in the presence of cytokines a level of apoptosis comparable to that Figure 3e ), which led to 60% cell death in 3 days that was overridden by SCF addition (Figure 3e ). These results showed that K562 cells were not dependant on BCR-ABL signaling as long as the SCF receptor pathway was activated.
CML CD34 þ cells are dependent on BCR-ABL only in the absence of SCF To investigate whether SCF alone was able to rescue CML CD34 þ cells from BCR-ABL tyrosine kinase inhibition, five samples of CML bone marrow mononuclear cells were cultured with FCS alone, in the presence of the cytokine cocktail or SCF. The spontaneous apoptosis, as well as imatinib-and nilotinibinduced apoptosis was then measured in CD34 þ cells by flow cytometry. Figure 4 shows that no significant effects were observed on spontaneous apoptosis (Figure 4a ) and imatinibinduced apoptosis (Figure 4b ). However, both the cytokine cocktail and SCF alone significantly inhibited nilotinib-induced apoptosis (Po0.02). This confirms indirectly that, when BCR-ABL tyrosine kinase is inhibited, SCF is sufficient to maintain CD34 þ cells alive if CD117 tyrosine kinase is not inhibited.
Discussion
In this study , a simple functional flow cytometry assay was developed to evaluate apoptosis induced in CML BM samples by BCR-ABL tyrosine kinase inhibitors. The specificity of the flow cytometry assay for BCR-ABL-expressing cells was confirmed by nilotinib-and imatinib-induced apoptosis being significantly greater in CML CD34 þ cells than in total mononuclear cells. This is in accordance with the earlier finding that expression of the BCR-ABL tyrosine kinase is ten times higher in CD34 þ than in total mononuclear cells. 22 Nilotinib was found to be 100 times more potent than imatinib in the presence of FCS. This is the same order of magnitude as earlier results obtained by different methods. 2 However, the addition of a cocktail of cytokines decreased twice more nilotinib-induced apoptosis than imatinib-induced apoptosis. Both nilotinib and imatinib inhibit BCR-ABL tyrosine kinase but, at the concentrations used, imatinib also inhibits c-ABL, platelet-derived growth factor receptor and CD117 tyrosine kinases. 2 The effects on platelet-derived growth factor receptor cannot explain the difference between both molecules observed after addition of cytokines as FCS, which was present in all conditions tested, contained platelet-derived growth factor and c-ABL can be excluded as it is also inhibited by nilotinib. CD117 is a better candidate as the concentration of nilotinib used in this study was greatly below the IC50 for this receptor, whereas imatinib concentration was above the IC50. Moreover, we confirmed that a large majority of CML CD34 þ cells are CD117 þ , as described earlier, 23 and that CD117 þ cells are more prone to be rescued from the nilotinib toxicity by cytokines. Similar results were obtained on K562, a BCR-ABLexpressing, CD117 þ cell line, 11 and these effects were reversed in part by blocking SCF-CD117 signaling. This was further substantiated by the ability of SCF to reverse the effects of spontaneous cell death and proliferation inhibition induced by RNA-interference depletion of BCR-ABL in K562 cells. The dependence of K562 survival on BCR-ABL expression has earlier been proposed as an example of oncogene addiction, 15 although apoptosis of CML CD34 þ cells has been reported not to be significantly induced by imatinib in the presence of cytokines.
14 More recent results indicate that CML CD34 þ cells show a limited addiction to BCR-ABL kinase activity in the presence of cytokines, 18 and that cytokines maintain activation of kinases that are otherwise inhibited by both imatinib and high concentrations of nilotinib. 19 In light of the results presented here, a better interpretation would be in terms of active kinase addiction whatever the pathway reaching this activation step.
In addition, we show here that SCF is the cytokine that can rescue CML CD34 þ cells from nilotinib toxicity while preserving imatinib toxicity (Figure 4 ). This could be the reverse side of the better specificity of nilotinib towards BCR-ABL tyrosine kinase. By preserving CD117 activity, nilotinib made the cells susceptible to maintain a survival-compatible level of kinase activation in the presence of SCF. This could be an explanation for the resistance to nilotinib-induced apoptosis that has been described earlier in CML CD34 þ cells cultured in the presence of a cytokine cocktail, including SCF. 4 Similarly, we can expect some resistance to nilotinib in CD117 and BCR-ABL-expressing cells in vivo, due to environmental presentation of SCF by macrophages or stromal cells. Although mutations in the kinase domain of c-KIT have not yet been described in CML samples, 24 a constitutive activation of CD117 or an autocrine secretion of SCF could also result in a partly resistant phenotype to nilotinib, whereas a response to imatinib would be preserved. In light of these results, it is possible that the better specificity of nilotinib towards BCR-ABL is not an advantage, and that the main interest of this second-generation inhibitor would be its efficiency towards several mutated BCR-ABL forms that conferred resistance to imatinib. 2, 25 However, the plasma concentrations of nilotinib encountered in vivo 26 are much higher than the concentration necessary to achieve apoptosis induction in vitro in the absence of SCF. The necessity to inhibit CD117 tyrosine kinase could be the reason for the high doses of nilotinib used in murine models 2 or prescribed to the patients, 27 leading to plasma concentrations more than two logs higher than the in vitro IC95.
In conclusion, the results presented here suggest that inhibition of BCR-ABL oncogenic kinase restores the dependence of CML progenitor cells towards regulation by cytokine environment and particularly by SCF.
